Update file human-practices.tsx

src/contents/human-practices.tsx

@@ -136,16 +136,18 @@ Our iGEM project, focusing on innovative treatment for hepatic encephalopathy (<
         <li><span className='bold-font'>General public</span>: As raising awareness and educating people about HE can significantly contribute to early diagnosis and treatment, ultimately benefiting the healthcare ecosystem as a whole.</li>
       </ul>
       </p>
-            <h3 >5.1. Stakeholder Identification</h3>
-                    <p className='indent'>
-      Our iGEM project, focusing on innovative treatment for hepatic encephalopathy (<span className='bold-font'>HE</span>), has identified key stakeholders critical to the success and real-world application of our research. These stakeholders include HE patients, medical professionals (doctors), pharmaceutical company representatives, research experts involved in HE-related studies, and the general public. 
-            <ul style={{ listStyleType: 'disc', paddingLeft: '20px' }}>
-              <li><span className='bold-font'>Patients</span>: Suffering from HE represent a primary stakeholder, as their quality of life directly depends on effective treatment options. </li>
-              <li><span className='bold-font'>Doctors</span>: Especially hepatologists and neurologists, are integral in diagnosing and treating HE, providing us with valuable insights into clinical needs. Pharmaceutical company representatives: They are vital for translating research into market-ready therapies, ensuring accessibility and scalability of our solutions.</li>
-              <li><span className='bold-font'>Researchers</span>: Including academics and specialists in liver disease, are critical for guiding the scientific direction of the project. </li>
-              <li><span className='bold-font'>General public</span>: As raising awareness and educating people about HE can significantly contribute to early diagnosis and treatment, ultimately benefiting the healthcare ecosystem as a whole.</li>
-            </ul>
-            </p>
+      </div>
+      <div className="rounded-border">
+              <h3 >5.1. Stakeholder Identification</h3>
+              <p className='indent'>
+Our iGEM project, focusing on innovative treatment for hepatic encephalopathy (<span className='bold-font'>HE</span>), has identified key stakeholders critical to the success and real-world application of our research. These stakeholders include HE patients, medical professionals (doctors), pharmaceutical company representatives, research experts involved in HE-related studies, and the general public. 
+      <ul style={{ listStyleType: 'disc', paddingLeft: '20px' }}>
+        <li><span className='bold-font'>Patients</span>: Suffering from HE represent a primary stakeholder, as their quality of life directly depends on effective treatment options. </li>
+        <li><span className='bold-font'>Doctors</span>: Especially hepatologists and neurologists, are integral in diagnosing and treating HE, providing us with valuable insights into clinical needs. Pharmaceutical company representatives: They are vital for translating research into market-ready therapies, ensuring accessibility and scalability of our solutions.</li>
+        <li><span className='bold-font'>Researchers</span>: Including academics and specialists in liver disease, are critical for guiding the scientific direction of the project. </li>
+        <li><span className='bold-font'>General public</span>: As raising awareness and educating people about HE can significantly contribute to early diagnosis and treatment, ultimately benefiting the healthcare ecosystem as a whole.</li>
+      </ul>
+      </p>
       </div>
               </Element>